相关实验视频
Updated: Jun 15, 2025

08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.2K
中和氧化酸丁胆降低呼吸道炎症和过度反应性在过敏喘的小鼠模型
Jignesh Vaghasiya1,2, Aruni Jha1,2, Sujata Basu1,2
1Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB R3E 3P4, Canada.
Biology
|August 28, 2024
概括
在喘小鼠模型中,用E06抗体中和氧化酸胆 (OxPCs) 降低了呼吸道炎症和高反应性. 这表明OxPCs是过敏性肺病的关键调解者.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 氧化压力研究研究 氧化压力研究
背景情况:
- 氧化应激与喘病因产生有关.
- 氧化脂胆 (OxPCs) 在过敏反应期间在肺部积累.
- 氧化PC积累的机制及其在过敏呼吸道炎症中的作用尚未完全理解.
研究的目的:
- 研究OxPCs在过敏呼吸道病理生理学中的作用.
- 测试E06单克隆抗体 (mAb) 在中和OxPCs中的有效性.
- 评估E06 mAb在小鼠喘模型中改善过敏原诱导的呼吸道炎症和过敏反应的能力.
主要方法:
- 成年BALB/c小鼠被室内灰尘虫 (HDM) 通过鼻腔挑战.
- 在HDM挑战之前,E06 mAb被注射入鼻.
- 分析了抗氧化酶的基因表达,支气管洗液 (BALF) 中的免疫细胞计数,细胞因子水平和呼吸道阻力.
主要成果:
- HDM挑战减少了抗氧化剂基因表达和增加了肺部免疫细胞透.
- 在BALF中,E06 mAb治疗显著降低了总免疫细胞,乙氨基,中性,巨细胞和淋巴细胞.
- E06 mAb治疗降低了促炎性细胞因子 (TNF,IL-1β) 和抑制了呼吸道和小气道抵抗的增加.
结论:
- 对OxPC中和性E06抗体的预防性施用有效地限制了过敏原诱导的气道炎症和过敏反应.
- OxPCs是氧化应激相关的过敏性肺病理生理学的重要调解者.
- 向OxPCs代表了对过敏性喘的潜在治疗策略.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
251
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
251
Asthma: Pathogenesis and Management
374
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
374
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Antiasthma Drugs: Leukotriene Modifiers
253
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
253
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
Drugs Used in Lower Respiratory Disorders: Overview
362
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
362

